Arbutus announces positive Phase 2a data for imdusiran + VTP-300 in chronic HBV

Arbutus Biopharma Corp

Imdusiran + VTP-300 achieved statistically significant (p<0.05) lower HBsAg at 24 weeks post-EOT vs placebo.
80% treatment arm vs 16% placebo had HBsAg <100 IU/mL; 60% vs 0% <10 IU/mL at 24 weeks post-EOT.
84% of treatment arm patients met NA therapy discontinuation criteria vs 53% in placebo arm.
Treatment generally safe; no SAEs or Grade 3/4 AEs; injection-site reactions and transient ALT increases.
Additional cohort evaluating nivolumab combination fully enrolled; preliminary data expected H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.